4 results
Primary Objective: Assess the incidence of wound infections in patients treated with venous stenting and AV fistula and Prevena negative pressure wound therapy (NPWT).Secondary Objective(s): Assess the incidence of lymph leakage in patients treated…
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.